What are the key benefits of Geneva?
- Adaptable for a diverse patient population
- Interstitial option always available
- Precise treatment planning and accurate dose delivery
- Easy to use in current clinical workflows
The universal gynecological applicator
An estimated 570,000 women are diagnosed with cervical cancer each year. Geneva is a universal brachytherapy applicator, that is designed to be used for all cervical cancer patients up to stage IIB. Its modular set up offers a personalized solution for each patient, enabling a faster and more effective approach to care to be achieved that provides good outcomes for patients and practitioners. The wide range of ovoid sizes and interstitial tube also allows for treatment of post-hysterectomy patients and those with small pelvic anatomies, while the click-and-go system makes assembly easy.
Book a demonstration to experience Geneva first hand and gain access to treatment delivery planning software and delivery platforms.
Book a demo Download Geneva brochure
Geneva’s modular design makes treating a diverse patient population easier. Configured to suit every female pelvic anatomy, with an interstitial tube and wide range of ovoids (even as small as 13 mm), the universal gynecological applicator is designed to accommodate a wide variety of patients.
Speaking at the World Congress of Brachytherapy, Dr Carminia Lapuz from the Olivia Newton-John Cancer Wellness and Research Centre, highlighted Geneva’s hybrid nature which they found “very helpful” to treat a diverse patient population.
According to the radiation oncologist, Geneva is capable of treating a wide range of cervical cancer cases, assembles easily, provides excellent coverage of the uterine fundus and is less expensive than other hybrid applicators.
Geneva’s unique interstitial tube enables clinicians to reach cancerous tissue around the vaginal cuff following hysterectomy. Combined with the ProGuide needles and Guiding Tubes, the interstitial tube facilitates accurate and reproducible dose distributions and eliminates the need for free-hand needle placement.
Geneva has been adopted by many medical centres across the globe. This includes the Leiden University Medical Centre in the Netherlands, which selected the Geneva applicator due to its wide range of ovoid sizes and needle positions. They thought the Geneva would be an attractive addition to their selection due to its wide range of ovoid sizes and needle positions.
“Geneva has enlarged our range of possibilities to choose the optimal applicator for each patient, thereby enabling excellent tumor coverage and good sparing of the organs at risk. The overall result is highly individualized cancer care.”
Leiden University Medical Centre
Read moreGeneva’s fixed geometry ensures accurate planning and reproducible dosimetric results.
Geneva is compatible with state-of-the-art Elekta treatment delivery platforms, such as the Flexitron® afterloader and Oncentra Brachy treatment planning software.
Geneva is included in the Oncentra Brachy applicator modeling module, which means reconstruction only takes a few mouse clicks.
Physicists want to quickly introduce new medical equipment into practice but they must be able to verify the proper functioning of the device.
This white paper provides a guideline for commissioning Geneva that enables users worldwide to introduce the applicator into clinical practice swiftly, with high and reproducible quality.
Download white paper Speak to a specialistGeneva is easy to assemble without the need for small screws or additional tools. Using the unique Elekta click system, the applicator is ready for use in just four clicks, ensuring a faster workflow.
Due to this, clinicians at the Olivia Newton-John Wellness and Research Centre say that Geneva has become their preferred applicator of choice, accounting for three out of every four treatments.
"Geneva assembly requires no screws – it takes literally four clicks and it’s assembled."
Read moreGeneva can be configured to suit most female pelvic anatomies. From the smallest ovoid size (13 mm) to the largest (40 mm), the intrauterine tube is available in six different lengths (0 and 30 to 80 mm) and at three different angles (15°, 30°, and 45°).
In the past, clinicians had to choose from a wide range of different gynecological applicators to treat the most common cervical cancer cases (stages I and II). Many of these applicators are challenging to assemble and require free-hand needles for patients that need treatment following a hysterectomy. Geneva addresses the inherent challenges of previous generation gynecological applicators and offers all the advantages of each of its predecessors, with enhanced functionality and user experience. Now clinicians need only one applicator to treat most cervical cancer patients up to IIB.
Geneva supports all image-guided BT treatments, and can be used with MR and CT imaging modalities. This gives rigidity and fully supports image-guided adaptive brachytherapy (IGABT) due to the interstitial option.
Geneva ensures that the option for guided interstitial brachytherapy is always available, even with the smallest ovoids, for optimal target coverage.
Geneva can be used post hysterectomy with the unique Interstitial Tube. You can now insert a needle in between the ovoids in a more precise way, using a Proguide needle together with an Elekta Guiding Tube.
Geneva is MR safe, just like many other Elekta applicators. It works with Ultrasound, X-ray, CT, and MRI imaging to provide good imaging results without artifacts or distortion. Image guidance is possible under CT, ultrasound and even MR. This is unique for Elekta applicators; it contains no metal parts.
Geneva applicator is CE Marked and has U.S. FDA 510(k) clearance. Contact us to find out what’s available in your country
Geneva is part of the Applicator Modeling and Implant Modeling modules in Oncentra® Brachy treatment planning. The applicator model allows rapid reconstruction in a few mouse clicks. The applicator’s fixed and stable geometry ensures accurate planning and reproducible dosimetric results. Geneva fits seamlessly into current 2D and 3D image modalities. It is compatible with Oncentra Brachy treatment planning software (version 4.5.3 and higher) and state-of-the-art Elekta treatment delivery platforms, such as the Flexitron® digital afterloader.
Geneva is available with an Interstitial Tube which can be used instead of an Intrauterine Tube. The Interstitial Tube is unique and enables clinicians to deliver the dose beyond the vaginal cuff following a hysterectomy.
Venezia is designed for advanced cervical cancer up to stage IV, with the possibility of inserting oblique needles through the lunar shaped ovoids, and support the insertion of interstitial needles from the perineum by making use of the perineal template. Geneva is designed to treat cervical cancer up to stage IIB and has a unique interstitial tube where you can treat patients who had a hysterectomy, more accurately through a ProGuide needle and Guiding Tube. Geneva also offers the smallest ovoid of 13mm, with even an option to insert interstitial needles.
To find out more about Geneva, speak to an Elekta expert or book a demonstration, please get in touch.